Cv Sciences Stock Price, News & Analysis

CV Sciences (OTCQB:CVSI), a consumer wellness company focused on hemp extracts, reported its Q2 2025 financial results. Revenue reached $3.6 million, down 8% from Q2 2024's $4.0 million, primarily due to state regulatory pressures affecting sales volume.

The company achieved its highest gross margin in 23 quarters at 50.9%, up from 47.0% in Q2 2024. CV Sciences reported positive adjusted EBITDA of $0.1 million, its first positive EBITDA since Q2 2019, compared to a $6,000 loss in Q2 2024. Cash balance improved to $0.9 million from $0.5 million at 2024 year-end.

Notably, 39% of Q2 2025 revenue came from new products launched since January 2023, with 34 new products introduced during this period. The company continues to focus on organic growth through product development and M&A opportunities while working to improve profitability through in-sourcing production via its Elevated Softgels acquisition.

CV Sciences (OTCQB:CVSI), a consumer wellness company focused on hemp extracts and natural ingredients, has scheduled its Q2 2025 earnings release for August 13, 2025 after market close.

The company will host a conference call with investors at 1:30 PM PT / 4:30 PM ET on the same day. Investors can access the webcast through the company's IR website or dial in directly. A replay will be available until August 20, 2025.

CV Sciences (OTCQB:CVSI), a consumer wellness company focused on hemp extracts, commends Texas Governor Greg Abbott's decision to veto Senate Bill 3. The bill would have effectively banned the sale of consumable hemp products in Texas.

The vetoed legislation posed a significant threat to Texas's hemp industry, which provides employment to thousands and supplies wellness products statewide. Governor Abbott emphasized the need for a regulatory framework that ensures public safety, aligns with federal law, maintains proper enforcement funding, and can be implemented without delays.

CV Sciences reported Q1 2025 financial results with revenue of $3.6 million, down 10% from $4.0 million in Q1 2024. The company achieved a gross margin of 46.0% and improved its adjusted EBITDA loss to $0.3 million, a 40% improvement from Q1 2024. Key developments include securing $1.2 million in financing and launching Lunar Fox, a new plant-based product line. The company reported an operating income of $11,000, compared to a $0.6 million loss in Q1 2024, primarily due to a $0.5 million reversal of accrued payroll taxes. Cash balance stood at $0.8 million, up from $0.5 million at end-2024. Notable is that 35% of Q1 2025 revenue came from new products launched since January 2023.

CV Sciences (OTCQB:CVSI), a consumer wellness company focused on hemp extracts and natural ingredients, has scheduled its Q1 2025 earnings release for May 14, 2025, after market close. The company will host a conference call with investors at 1:00 p.m. Pacific Time (4:00 p.m. Eastern Time) on the same day.

Investors can access the webcast through the company's Investor Relations website or dial in directly. U.S. participants can call (877) 407-0784, while international callers should use (201) 689-8560. A replay will be available until May 21, 2025, accessible by dialing (844) 512-2921 (U.S.) or (412) 317-6671 (international) with confirmation code 13753631.

CV Sciences (OTCQB:CVSI) reported its fiscal year 2024 results with revenue of $15.7 million, slightly down 1.9% from $16.0 million in 2023. The company's Q4 2024 revenue was $3.9 million, up 2.2% from $3.8 million in Q4 2023.

Key financial metrics include improved gross margin of 45.6% for 2024 (up from 44.3% in 2023), reduced operating expenses by 5.4% to $9.4 million, and an adjusted EBITDA loss of $0.8 million, significantly improved from a $2.3 million loss in 2023.

Notable developments include the acquisition of Elevated Softgels, launch of +PlusHLTH™ supplement line, partnership with Chewy for pet products, and introduction of Lunar Fox vegan food line. The company maintained its position as the top-selling hemp extract brand in natural product retail.

CV Sciences (OTCQB:CVSI) has launched Lunar Fox Food Co., a new line of plant-based food products targeting the growing vegan market. The product line includes seven innovative offerings: CHEDDRLY MAC! (vegan mac and cheese), CHEDDRLY! (dairy-free cheese substitute), WHISKED! (egg substitute for omelets), BAKED! (dairy-free egg alternative for baking), MANGIA! (Italian-seasoned meatless alternative), FIESTA! (Mexican-spiced meatless alternative), and BOLOGNESE! (plant-based Italian sauce).

All products are 100% natural, gluten-free, and available at select retailers and through lunarfoxfoods.com. This launch expands CV Sciences' portfolio, which includes +PlusHLTH cannabinoid-free supplements, +PlusCBD Extra Support Gummies, Reserve gummies, and pet products.

CV Sciences (OTCQB:CVSI), a consumer wellness company focused on hemp extracts and natural ingredients, has scheduled its Year End and Fourth Quarter 2024 financial results announcement for March 27, 2025, before market opening.

The company will host a conference call with investors at 7:00 a.m. Pacific Time (10:00 a.m. Eastern Time) on the same day. Investors can participate through a webcast available on the company's Investor Relations website or by dialing (877) 407-0784 for U.S. callers or (201) 689-8560 for international participants.

A replay of the call will be accessible until April 3, 2025, by dialing (844) 512-2921 (U.S.) or (412) 317-6671 (international) with confirmation code 13752212.

CV Sciences (OTCQB:CVSI) has launched new 2.5 mg THC Fizz Tablets as part of their Aura Collection product line. The lemon-flavored, fast-acting tablets are designed to be dissolved in beverages, offering an alcohol-free alternative for relaxation and stress relief. The vegan and gluten-free tablets are made with premium hemp extract and are now available at select retailers and the company's website.

This launch follows the September 2024 introduction of the Aura Collection, which includes Serene and Illuminate Gummies combining THC and CBD. The expansion adds to CV Sciences' growing portfolio, which recently added +PlusHLTH™ cannabinoid-free supplements, +PlusCBD™ Reserve gummies, and +PlusCBD™ pet products.